意美(阿瑞匹坦胶囊)可不可以长期用药?多久生效？

Yimei (Aprepitant Capsules), administered in combination with other antiemetic drugs, is suitable for the prevention of acute and delayed nausea and vomiting that occurs during initial and repeated treatments of highly emetogenic anti-tumor chemotherapy. (Aprepitant Capsules) has been in the first-line recommended position in the anti-emetic regimen of chemotherapy drugs with a high risk of vomiting since its launch, and its efficacy and safety have been clinically recognized. Today, let’s find out whether Yimei (Aprepitant Capsules) can be used for a long time? How long does it take to take effect?

Yimei Usage and Dosage:

Imeda is a three-day intervention and includes a course of treatment with a corticosteroid and a 5-HT3 antagonist. The recommended dose of Yimei is 125 mg taken orally one hour before chemotherapy on the first day, and 80 mg once daily in the morning on the second and third days.

The specific effects of Yimei Aprepitant Capsules vary from person to person, but generally speaking, the therapeutic effect of this drug is relatively obvious. People who want to use this drug can consult a doctor.

The main component of Yimei Aprepitant Capsules is aprepitant, which has a unique mode of action; it is a selective high-affinity antagonist of the human substance P neurokinin 1 (NK1) receptor.

Counter-screening assays indicate that aprepitant is at least 3,000 times more selective for NK1 receptors than other enzymes, transporters, ion channels and receptor sites, including dopamine and serotonin receptors, compared to other drugs for the treatment of chemotherapy-induced vomiting (CINV).

Preclinical studies have shown that aprepitant has a long-lasting effect on the central system and can inhibit cisplatin-induced vomiting in the acute and delayed phases, thereby enhancing the antiemetic 5-HT3-receptor antagonist ondansetron and the leather steroid dexamethasone against cisplatin-induced vomiting.

As a first-line drug and recommended drug for preventing nausea and vomiting caused by highly emetogenic anti-tumor chemotherapy, aprepitant has been unanimously recommended by authoritative European and American guidelines such as the National Comprehensive Cancer Network Clinical Application Guidelines (NCCN).

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.